Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Cancer|April 14, 2015
A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancerDonna M Graham, Wanrudee Isaranuwatchai, Steven Habbous, et al.Future Oncology (London, England)|October 9, 2024
Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based populationTom Waddell, Manon Pillai, Kate Armitage, et al.JCO Clinical Cancer Informatics|January 19, 2023
Digital ECMT Cancer Trial Matching Tool: an Open Source Research Application to Support Oncologists in the Identification of Precision Medicine Clinical TrialsPaul O'Regan, Richard Hoskins, Christopher Grave, et al.Cancer Medicine|October 9, 2025
Patient and Clinician Perspectives on the Communication of Genomic Results in Cancer CareEleanor Johnston, Zoulikha Zair, Leanna Goodwin, et al.Journal of Immunotherapy and Precision Oncology|September 10, 2025
Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical TrialsSammy Shaya, Okezie Uche-Ikonne, Bedirhan Kilerci, et al.Cancer|July 20, 2024
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 StudyHyun Cheol Chung, Esma Saada-Bouzid, Federico Longo, et al.Frontiers in Digital Health|December 15, 2025
UpSMART: five years of digital innovation in cancer clinical research-achievements, challenges, and recommendationsPaul O'Regan, Fouziah Butt, Louise Carter, et al.Cell Reports. Medicine|December 6, 2023
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trialJenna H Rannikko, Loic Verlingue, Maria de Miguel, et al.BMC Cancer|September 14, 2017
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerKerry Lynn Reynolds, Philippe L Bedard, Se-Hoon Lee, et al.Scientific Reports|January 19, 2020
Latency and interval therapy affect the evolution in metastatic colorectal cancerHamid Nikbakht, Selin Jessa, Mahadeo A Sukhai, et al.Pageof 3